Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis

被引：0
|
作者：
Wollenberg, A. [1 ]
Soong, W. [2 ]
Goooderham, M. [3 ,4 ]
Bissonnette, R. [5 ]
Xiao, J. [6 ]
Khokhar, F. A. [6 ]
Marco, A. R. [7 ]
Levit, N. A. [6 ]
Shabbir, A. [6 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Munich, Germany
[2] Alabama Allergy & Asthma Ctr, Birmingham, AL USA
[3] SKiN Ctr Dermatol, Peterborough, ON, Canada
[4] Queens Univ, Kingston, ON, Canada
[5] Innovaderm Res, Montreal, PQ, Canada
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Sanofi Genzyme, Madrid, Spain
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 186卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
669
引用
收藏
页码：E163 / E163
页数：1
相关论文
共 50 条
  • [1] LONG-TERM SAFETY DATA FOR DUPILUMAB UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Wollenberg, Andreas
    Deleuran, Mette
    Soong, Weily
    Gooderham, Melinda
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    [J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 35
  • [2] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Gooderham, Melinda
    Wollenberg, Andreas
    Soong, Weily
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Marco, Ainara Rodriguez
    Levit, Noah A.
    Shabbir, Arsalan
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 561 - 561
  • [3] Dupilumab provides long-term efficacy for up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Thyssen, J. P.
    Blauvelt, A.
    Lockshin, B.
    Galus, R.
    Lynde, C.
    Xiao, J.
    Levit, N. A.
    Marco, A. R.
    Shabbir, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E162 - E162
  • [4] DUPILUMAB PROVIDES LONG-TERM EFFICACY FOR UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Deleuran, Mette
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Lockshin, Benjamin
    Galus, Ryszard
    Lynde, Charles
    Xiao, Jing
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    [J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 34
  • [5] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: open-label extension study
    Blauvelt, A.
    Wollenberg, A.
    Beck, L. A.
    Chen, Z.
    Vakil, J.
    Khokhar, F. A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E120 - E121
  • [6] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Open-Label Extension (OLE) study
    Blauvelt, A.
    Wollenberg, A.
    Chen, Z.
    Bastian, M.
    Zhang, M.
    Khokhar, F. A.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 65 - 66
  • [7] Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years
    Wollenberg, Andreas
    Soong, Weily
    Goooderham, Melinda
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB106 - AB106
  • [8] Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension study
    Blauvelt, A.
    Wollenberg, A.
    Eichenfield, L.
    Chen, Z.
    Sierka, D.
    Vakil, J.
    Khokhar, F. A.
    Cyr, S. L.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E121 - E121
  • [9] Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years
    Beck, Lisa A.
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Takeshi
    Galus, Ryszard
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Xiao, Jing
    Dingman, Robert
    Xu, Christine
    Avetisova, Elena
    Dubost-Brama, Ariane
    Shabbir, Arsalan
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [10] Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension (OLE) study
    Blauvelt, Andrew
    Wollenberg, Andreas
    Eichenfield, Lawrence
    Chen, Zhen
    Sierka, Debra
    Khokhar, Faisal A.
    Shumel, Brad
    Cyr, Sonya L.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB143 - AB143
12345